Abstract:Background: Recently, long non-coding RNAs (lncRNAs) are important populations of noncoding RNAs with defined key roles in normal breast development as well as breast tumorigenesis. Triple-negative breast cancer (TNBC) is a particular breast cancer subtype with poor prognosis because of highly invasive and no specific drug treatment yet. Breast cancer stems cells (BCSCs) cause a high risk of invasion, metastasis and drug resistance for breast cancer patients. Methods: Two microarrays of BCSCs and no-BCSCs were isolated from mammosphere-3D-cultured MCF-7 cells, differentially expressed lncRNAs (DELs) were screened out by Gene Expression Omnibus (GEO). Gene ontology enrichment analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were also performed to analyze DELs features. Using the STRING database to analyze DELs interaction network module to further screen the hub lncRNAs related to tumor stemness and make functional annotations. The expressions of hub DELs were validated using data from The Cancer Genome Atlas database. In addition, the expression analysis and survival analysis were conducted using GEO was utilized to analyze DELs in TNBC using GEPIA database. Results: A total of 143 aberrantly expressed lncRNAs in BCSCs were identified, and 25 lncRNAs were downregulated and 118 lncRNAs were upregulated compared to non-BCSCs. Up- and downregulated top 3 lncRNAs were selected and verified by RT-PCR. Notably, GO enrichment analysis and KEGG pathway analysis indicated that RNA transport, spliceosome, oxidative phosphorylation, NOD-like receptor signaling pathway, PI3K-Akt signaling pathway, and metabolic pathways may serve important roles in BCSCs. Additionally, the function loss assay indicated that ZGRF1 positively upregulated phenotype and biological functions of BCSCs in vitro. Collectively, our work establishes the lncRNAs signature in BCSCs and these findings assess us with evidence to explore further functionalities of lncRNAs in BCSCs and provide a novel therapeutic strategy for breast cancer. Conclusion: Our work establishes the lncRNAs signature in BCSCs and these findings assess us with evidence to explore further functionalities of lncRNAs in BCSCs and provide a novel therapeutic strategy for breast cancer. ZGRF1 expression is upregulated in TNBC patients and has a poor prognosis, which can be promising biomarkers.

Decreased expression of lncRNA MEG 3 in breast cancer is associated with poor prognosis

ZGRF1 is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics.

High expression of lncRNA MEG3 participates in non-small cell lung cancer by regulating microRNA-7-5p

Downregulated Long Noncoding Rna Meg3 is Associated with Poor Prognosis and Promotes Cell Proliferation in Gastric Cancer

Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression

The Biological Roles and Molecular Mechanisms of Long Non-Coding RNA MEG3 in the Hallmarks of Cancer

Long non-coding RNA MEG3 functions as a competing endogenous RNA of miR-93 to regulate bladder cancer progression via PI3K/AKT/mTOR pathway

Association of LncRNA MEG3 Polymorphisms with Efficacy of Neoadjuvant Chemotherapy in Breast Cancer

Long Non-Coding Rna Meg3 Functions As A Tumour Suppressor And Has Prognostic Predictive Value In Human Pancreatic Cancer

Long Noncoding RNA MEG3 is Downregulated in Cervical Cancer and Affects Cell Proliferation and Apoptosis by Regulating Mir-21

LncRNA MEG3 inhibits cell proliferation and induces apoptosis in laryngeal cancer via miR‐23a/APAF‐1 axis

Role of BC040587 As a Predictor of Poor Outcome in Breast Cancer

LncRNA MEG3 Inhibit Endometrial Carcinoma Tumorigenesis and Progression Through PI3K Pathway

Meg3 is A Prognostic Factor for Crc and Promotes Chemosensitivity by Enhancing Oxaliplatin-Induced Cell Apoptosis

Downregulation of Long Noncoding RNA MEG3 is Associated with Poor Prognosis and Promoter Hypermethylation in Cervical Cancer

LncRNA MEG3 has anti-activity effects of cervical cancer.

Upregulation LncRNA MEG3 expression suppresses proliferation and metastasis in melanoma via miR-208/SOX4

Relationship Between Clinicopathological Effects And Prognosis Of Triple Negative Breast Cancer And Lncrna00310

Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma

LncRNA Meg3 Suppresses Hepatocellular Carcinoma in Vitro and Vivo Studies

MEG3 Inhibits Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition in Laryngeal Squamous Cell Carcinoma.